UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Risk factors for NSAID‐associated upper GI clinical events in a long‐term prospective study of 34 701 arthritis patients

Alimentary pharmacology & therapeutics, 2010-11, Vol.32 (10), p.1240-1248

2010

Volltextzugriff (PDF)

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2015-12, Vol.17 (12), p.1180-1193

2015

Volltextzugriff (PDF)

Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction

JAMA : the journal of the American Medical Association, 2000-06, Vol.283 (22), p.2941

2000

Volltextzugriff (PDF)

Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs

Circulation (New York, N.Y.), 2000-01, Vol.101 (2), p.125-130

2000

Volltextzugriff (PDF)

Prescription rates of protective co‐therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines

Alimentary pharmacology & therapeutics, 2009-10, Vol.30 (7), p.767-774

2009

Volltextzugriff (PDF)

Combination therapy in the management of mixed dyslipidaemia

Journal of internal medicine, 2008-04, Vol.263 (4), p.353-365

Cannon, C. P.

2008

Volltextzugriff (PDF)

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

The New England journal of medicine, 2020-10, Vol.383 (15), p.1425-1435

2020

Volltextzugriff (PDF)

Association between white blood cell count, epicardial blood flow, Myocardial perfusion, and clinical outcomes in the setting of acute Myocardial Infarction: A Thrombolysis in Myocardial Infarction 10 Substudy

Circulation (New York, N.Y.), 2000-11, Vol.102 (19), p.2329-2334

2000

Volltextzugriff (PDF)

Influence of stroke subtype on quality of care in the Get With The Guidelines-Stroke Program

Neurology, 2009-09, Vol.73 (9), p.709-716

2009

Volltextzugriff (PDF)

Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial

Circulation (New York, N.Y.), 2000-07, Vol.102 (2), p.149-156

2000

Volltextzugriff (PDF)

The antiplatelet effects of ticlopidine and clopidogrel

Annals of internal medicine, 1998-09, Vol.129 (5), p.394

1998

Volltextzugriff (PDF)

TIMI frame count : a quantitative method of assessing coronary artery flow

Circulation (New York, N.Y.), 1996-03, Vol.93 (5), p.879-888

1996

Volltextzugriff (PDF)

National academy of clinical biochemistry laboratory medicine practice guidelines : Clinical characteristics and utilization of biochemical markers in acute coronary syndromes

Clinical chemistry (Baltimore, Md.), 2007-04, Vol.53 (4), p.552-574

2007

Volltextzugriff (PDF)

Critical pathways : A review

Circulation (New York, N.Y.), 2000-02, Vol.101 (4), p.461-465

2000

Volltextzugriff (PDF)

Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes

European heart journal, 2009-05, Vol.30 (10), p.1195-1202

2009

Volltextzugriff (PDF)

TNK-tissue plasminogen activator in acute myocardial infarction : Results of the thrombolysis in myocardial infarction (TIMI) 10A dose-ranging trial

Circulation (New York, N.Y.), 1997-01, Vol.95 (2), p.351-356

1997

Volltextzugriff (PDF)

C-Reactive Protein Levels and Outcomes after Statin Therapy

The New England journal of medicine, 2005-01, Vol.352 (1), p.20-28

2005

Volltextzugriff (PDF)

Cardiac-Specific Troponin I Levels to Predict the Risk of Mortality in Patients with Acute Coronary Syndromes

The New England journal of medicine, 1996-10, Vol.335 (18), p.1342-1349

1996

Volltextzugriff (PDF)

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL) – A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: trial design, recruitment and baseline characteristics

The American heart journal, 2017-05, Vol.187, p.182-190

Landray, Martin J

2017

Volltextzugriff (PDF)

The NCDR ACTION Registry–GWTG: transforming contemporary acute myocardial infarction clinical care

Heart (British Cardiac Society), 2010-11, Vol.96 (22), p.1798-1802

2010

Volltextzugriff (PDF)

Myocardial infarction: contemporary management strategies

Journal of internal medicine, 2007-07, Vol.262 (1), p.59-77

2007

Volltextzugriff (PDF)

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of Cardiac Troponin and B-Type Natriuretic Peptide or N-Terminal proB-Type Natriuretic Peptide for Etiologies Other than Acute Coronary Syndromes and Heart Failure

Clinical chemistry (Baltimore, Md.), 2007-12, Vol.53 (12), p.2086-2096

2007

Volltextzugriff (PDF)

Impact of ADCY9 Genotype on Response to Anacetrapib

Circulation (New York, N.Y.), 2019-09, Vol.140 (11), p.891-898

2019

Volltextzugriff (PDF)

Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial

International journal of clinical practice (Esher), 2009-04, Vol.63 (4), p.667-670

2009

Volltextzugriff (PDF)

National academy of clinical biochemistry and IFCC committee for standardization of markers of cardiac damage laboratory medicine practice guidelines : Analytical issues for biochemical markers of acute coronary syndromes

Clinical chemistry (Baltimore, Md.), 2007-04, Vol.53 (4), p.547-551

APPLE, Fred S

2007

Volltextzugriff (PDF)

1 – 25 von 2.544

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.293)
Mit Volltextzugriff
(2.150)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.671)
Life Sciences & Biomedicine
(1.325)
Humans
(1.165)
Female
(751)
Male
(746)
Biological And Medical Sciences
(604)
Medical Sciences
(547)
Middle Aged
(526)
Cardiovascular System & Cardiology
(479)
Cardiac & Cardiovascular Systems
(457)
Aged
(435)
Adult
(288)
Physical Sciences
(288)
Treatment Outcome
(236)
Cardiology. Vascular System
(232)
Risk Factors
(224)
Heart
(220)
Astronomy & Astrophysics
(191)
Coronary Heart Disease
(186)
Heart Attacks
(181)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(16)
... seit 30 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Risk factors for NSAID‐associated upper GI clinical events in a long‐term prospective study of 34 701 arthritis patients

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction

Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs

Prescription rates of protective co‐therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines

Combination therapy in the management of mixed dyslipidaemia

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

Association between white blood cell count, epicardial blood flow, Myocardial perfusion, and clinical outcomes in the setting of acute Myocardial Infarction: A Thrombolysis in Myocardial Infarction 10 Substudy

Influence of stroke subtype on quality of care in the Get With The Guidelines-Stroke Program

Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial

The antiplatelet effects of ticlopidine and clopidogrel

TIMI frame count : a quantitative method of assessing coronary artery flow

National academy of clinical biochemistry laboratory medicine practice guidelines : Clinical characteristics and utilization of biochemical markers in acute coronary syndromes

Critical pathways : A review

Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes

TNK-tissue plasminogen activator in acute myocardial infarction : Results of the thrombolysis in myocardial infarction (TIMI) 10A dose-ranging trial

C-Reactive Protein Levels and Outcomes after Statin Therapy

Cardiac-Specific Troponin I Levels to Predict the Risk of Mortality in Patients with Acute Coronary Syndromes

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL) – A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: trial design, recruitment and baseline characteristics

The NCDR ACTION Registry–GWTG: transforming contemporary acute myocardial infarction clinical care

Myocardial infarction: contemporary management strategies

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of Cardiac Troponin and B-Type Natriuretic Peptide or N-Terminal proB-Type Natriuretic Peptide for Etiologies Other than Acute Coronary Syndromes and Heart Failure

Impact of ADCY9 Genotype on Response to Anacetrapib

Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial

National academy of clinical biochemistry and IFCC committee for standardization of markers of cardiac damage laboratory medicine practice guidelines : Analytical issues for biochemical markers of acute coronary syndromes

Suchergebnisse filtern